Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shilpa Medicare Limited ( (IN:SHILPAMED) ).
Shilpa Medicare has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Rotigotine transdermal patches in multiple strengths, its first-ever transdermal patch submission to the US market and a generic version of Neupro indicated for Parkinson’s disease and Restless Legs Syndrome in a US market estimated at about $112 million. The filing, originating from the company’s USFDA- and Europe-approved Unit VI facility near Bengaluru that manufactures specialized dosage forms including transdermal patches and oral mouth-dissolving films, marks a strategic milestone that deepens Shilpa’s presence in complex generics and advanced drug delivery systems, potentially strengthening its competitive positioning in the US pharmaceutical market and expanding treatment options for neurological patients.
More about Shilpa Medicare Limited
Shilpa Medicare Limited is a leading Indian pharmaceutical company specializing in the development, manufacture and marketing of active pharmaceutical ingredients (APIs), finished formulations and biologics, with a focus on oncology, infectious diseases and specialty segments. Leveraging expertise in complex generics, novel drug delivery systems and contract development and manufacturing (CDMO) services, the company serves patients in more than 80 countries through a portfolio that includes advanced dosage forms such as oral dispersible films and transdermal systems.
Average Trading Volume: 13,695
Technical Sentiment Signal: Hold
Current Market Cap: 61.08B INR
See more data about SHILPAMED stock on TipRanks’ Stock Analysis page.